SMC Chair Dr Rob Peel said: "Semaglutide will provide a useful treatment option to help reduce major cardiovascular events in patients who are overweight and have cardiovascular disease." Speaking after the announcement, Sebnem Avsar Tuna, General Manager Novo Nordisk UK said: We are delighted that the SMC has recognised the value semaglutide can bring to the people in Scotland who are living with established cardiovascular disease and overweight or obesity, where the threat of a secondary event is a constant reality
Supplement Considerations for MC1R rs1805008 Support Supplements cannot modify your MC1R rs1805008 genotype, but targeted supplementation can address nutritional gaps and support the biological pathways connected to Melanotan II and sexual health
Severe gastroparesis is a digestive disorder that slows or prevents the stomach from emptying food normally
Moringa Magic and Digestive Health: How It Supports a Balanced Gut A well-functioning digestive system is foundational to overall health, influencing everything from nutrient absorption to immune function
Levels of LDL-C, ApoB-100, Non-HDL Cholesterol and LDL-P as Markers for ASCVD Risk
Cardiovascular considerations : Severe caloric restriction can have adverse cardiac effects, including arrhythmias related to electrolyte disturbances
.png)
